Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

Informazioni relative al progetto

STROBE

ID dell’accordo di sovvenzione: 672768

DOI 10.3030/672768

Progetto chiuso

Data della firma CE 10 Aprile 2015

Data di avvio 1 Maggio 2015

Data di completamento 31 Ottobre 2015

Finanziato da

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Costo totale € 71 429,00

Contributo UE € 50 000,00

Coordinato da

CRITICAL PHARMACEUTICALS LIMITED
United Kingdom

Obiettivo

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.

Campo scientifico

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › chemical sciences › polymer sciences
• medical and health sciences › clinical medicine › ophthalmology
• medical and health sciences › medical biotechnology › cells technologies › stem cells

Programma(i)

• H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Argomento(i)

• NMP-25-2014-1 - Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs

Invito a presentare proposte

H2020-SMEInst-2014-2015

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEINST-1-2014

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

CRITICAL PHARMACEUTICALS LIMITED

• Contribution nette de l'UE: € 50 000,00
• Indirizzo: BIOCITY NOTTINGHAM - PENNYFOOT STREET ; NG1 1GF NOTTINGHAM ; Regno Unito
• PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì:
  Regione
  East Midlands (England) › Derbyshire and Nottinghamshire › Nottingham
• Regione: East Midlands (England) › Derbyshire and Nottinghamshire › Nottingham
• Tipo di attività: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Costo totale: € 71 429,00